STOCK TITAN
  1. Home
  2. Sec-filings
  3. CGON
  4. [144] CG Oncology, Inc. SEC Filing

CG Oncology: Ambaw Bellete plans 5,789-share sale

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

CG Oncology, Inc. (CGON) has a notice of proposed resale of its common stock under Rule 144 filed on behalf of Ambaw Bellete. The filing lists an arrangement through Morgan Stanley Smith Barney LLC – Executive Financial Services for the potential sale of 5,789 shares of common stock, with a closing date referenced as August 27, 2026.

The notice also lists multiple prior sales of CG Oncology common stock by Ambaw Bellete over the past three months, each with specific share amounts and total dollar values, indicating ongoing secondary market selling activity by this holder. These transactions relate to existing shares and a stock option exercise, rather than a new issuance by CG Oncology.

Positive

  • None.

Negative

  • None.
Shares registered for proposed sale 5,789 shares of common stock Listed under Securities To Be Sold with a stock option exercise, dated 08/27/2026
Recent sale on 08/25/2026 10,551 shares; $839,338.38 total value Common stock sale by Ambaw Bellete during the past 3 months
Recent sale on 08/19/2026 100,000 shares; $7,954,105.00 total value Common stock sale by Ambaw Bellete during the past 3 months
Recent sale on 08/17/2026 52,438 shares; $4,034,894.35 total value Common stock sale by Ambaw Bellete during the past 3 months
Recent sale on 08/11/2026 50,000 shares; $3,810,255.00 total value Common stock sale by Ambaw Bellete during the past 3 months
Recent sale on 07/28/2026 50,000 shares; $3,625,195.00 total value Common stock sale by Ambaw Bellete during the past 3 months
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
Securities To Be Sold regulatory
"144: Securities To Be Sold Common | 08/27/2026 | Stock Option Exercise"
Stock Option Exercise financial
"Common | 08/27/2026 | Stock Option Exercise | Issuer"
A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.
Executive Financial Services financial
"Common | Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza"
Common financial
"Common | 08/27/2026 | Stock Option Exercise | Issuer"

FAQ

What does the Form 144 filing for CGON disclose?
The Form 144 filing discloses that Ambaw Bellete plans a potential sale of 5,789 shares of CG Oncology, Inc. common stock through Morgan Stanley Smith Barney LLC, tied to a stock option exercise, with a closing date referenced as August 27, 2026.

Is CG Oncology, Inc. (CGON) issuing new shares in this Form 144?
No. The Form 144 relates to the resale of existing common shares for the account of Ambaw Bellete, including shares associated with a stock option exercise. The notice concerns secondary market sales, not a new capital-raising issuance by CG Oncology, Inc.

How many CGON shares are proposed to be sold under this new Form 144?
The notice lists 5,789 shares of CG Oncology, Inc. common stock under “Securities To Be Sold,” associated with a stock option exercise and a referenced closing date of August 27, 2026.

What recent CGON share sales by Ambaw Bellete are reported in the past 3 months?
The filing lists multiple sales of CG Oncology common stock by Ambaw Bellete between July 15, 2026 and August 25, 2026, each showing the trade date, number of shares, and total dollar value for those completed transactions.

On which market is CG Oncology, Inc. common stock traded according to this filing?
The securities information section states that CG Oncology, Inc. common stock is traded on NASDAQ, and the Form 144 relates to potential sales of that NASDAQ-listed common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Source: View Original Filing on SEC EDGAR